NICE Onpattro approval puts Alnylam back in hATTR running by Anna Smith | Jul 9, 2019 | News | 0 NICE issued the drug a preliminary ‘no’, back in December 2018. Read More
Alnylam’s novel RNA therapy Onpattro wins nod for hATTR amyloidosis by Selina McKee | Aug 13, 2018 | News | 0 The US Food and Drug Administration has approved Alnylam’s RNAi therapeutic Onpattro for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. Read More